Stryker Debuts Next-Gen Clot Remover For Ischemic Stroke, Boosting Neuro Competition
This article was originally published in The Gray Sheet
Executive Summary
Firm gains 510(k) clearance for Trevo Pro clot removal device for acute ischemic stroke, which will compete with Covidien’s Solitaire FR revascularization device.
You may also be interested in...
Endovascular Thrombectomy Shows No Benefit Over Standard Of Care In MR RESCUE
A National Institutes of Health-sponsored trial appears to dash hopes that CT or MR imaging can help select patients for acute stroke treatment with first-generation thrombus retrieval systems.
Endovascular Thrombectomy Shows No Benefit Over Standard Of Care In MR RESCUE
The National Institutes of Health-sponsored trial appears to dash hopes that CT or MRI can select patients for acute stroke treatment with first-generation thrombus retrieval systems.
Stryker M&A Strategy Intact Under New CEO With Latest Deal For Stroke Care
Purchase of Surpass Medical for $135 million represents Stryker’s 10th acquisition since 2009. The company affirmed its acquisition strategy focused on core and key adjacent markets during its Oct. 17 earnings call, but also sought to ratchet down earnings growth expectations in the near term to account for headwinds, including the upcoming U.S. medical device excise tax.